squamous cell carcinoma

Biotech

Checkpoint on track to add indications for cancer drug approval

Interim phase 1 results have sustained Checkpoint Therapeutics’ hopes for a second indication for its lead anti-PD-L1 antibody.
James Waldron Jun 16, 2022 3:49pm

Gilead joins Big Pharma peers at Dragonfly's pond in $300M deal

May 2, 2022 9:50am

Idera's only asset flounders as biotech, AbbVie end enrollment

Dec 15, 2021 11:15am

Cedilla adds $25M to series B to test two cancer drugs in trials

Oct 25, 2021 6:30am

New cancer targets unveiled in map of protein interactions

Oct 1, 2021 9:00am

Adlai Nortye bags another $100M for immuno-oncology pipeline

Jul 15, 2021 10:00am